Telesis Bio Inc EV/EBIT
What is the EV/EBIT of Telesis Bio Inc?
The EV/EBIT of Telesis Bio Inc is N/A
What is the definition of EV/EBIT?
Enterprise value to earnings before interest and taxes (EV/EBIT) is a financial ratio used to measure if a stock is priced appropriately to similar stocks and the market. It is similar to the P/E ratio.
ttm (trailing twelve months)
The EV/EBIT ratio addresses some of the shortcomings of the P/E ratio. Instead of taking market capitalization, the ratio uses enterprise value, as it takes into account the true value of the company. Enterprise value includes both equity and debt. It is calculated as:
Enterprise value = market cap + total debt – cash and cash equivalents
The EV/EBIT ratio is useful in comparing peers within the wider market. A high EV/EBIT ratio indicates that a company’s stock is overvalued. On the opposite, a low EV/EBIT ratio indicates that a company’s stock is undervalued. The lower the ratio, the more financially stable a company should be. However, investors and analyst should use other ratios and information to get a full picture of a company’s financial state and actual value.
EV/EBIT of companies in the Health Care sector on NASDAQ compared to Telesis Bio Inc
What does Telesis Bio Inc do?
sgi-dna, a wholly owned subsidiary of synthetic genomics inc., provides genomic solutions to advance scientific discovery. sgi-dna’s ever expanding suite of products, services, reagents, bioinformatics tools and instrumentation enables scientists to discover, design and build novel solutions for basic research, as well as for biomedical and industrial applications. sgi-dna’s genomic services include whole genome sequencing, dna synthesis, library design, bioinformatics, cell engineering, and plasmid dna cloning and purification. sgi-dna’s reagents include a complete suite of gibson assembly® and site directed mutagenesis kits as well as optimized cell lines such as vmax™ a novel, fast growing host system for molecular biology. to further enable synthetic biology workflows, sgi-dna offers the bioxp™ 3200 system. this fully automated genomics workstation allows the creation of double stranded dna fragments, automated cloning, as well as next generation sequencing dna library preparation.
Companies with ev/ebit similar to Telesis Bio Inc
- VBI Vaccines has EV/EBIT of N/A
- Novus Therapeutics Inc has EV/EBIT of N/A
- Sanwaria Consumer has EV/EBIT of N/A
- EP&T Global has EV/EBIT of N/A
- PDL Biopharma Inc has EV/EBIT of N/A
- Killi has EV/EBIT of N/A
- Telesis Bio Inc has EV/EBIT of N/A
- Iterum Therapeutics Plc has EV/EBIT of N/A
- Nuformix Plc has EV/EBIT of N/A
- Alvo Minerals Ltd has EV/EBIT of N/A
- NCS Multistage Inc has EV/EBIT of N/A
- DarioHealth Corp has EV/EBIT of N/A
- Edesa Biotech has EV/EBIT of N/A